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Abstract
This study evaluated whether GM2 ganglioside storage is necessary for neurodegeneration and neuroinflammation
by performing β-hexosaminidase rescue experiments in neurons of HexB−/− mice. We developed a novel mouse
model, whereby the expression of the human HEXB gene was targeted to neurons of HexB−/− mice by the Thy1
promoter. Despite β-hexosaminidase restoration in neurons was sufficient in rescuing HexB−/− mice from GM2
neuronal storage and neurodegeneration, brain inflammation persisted, including the presence of large numbers of
reactive microglia/macrophages due to persisting GM2 presence in this cell type. In conclusion, our results suggest
that neuroinflammation is not sufficient to elicit neurodegeneration as long as neuronal function is restored.
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Introduction
The pathognomonic feature of Sandhoff disease is GM2
ganglioside storage primarily in neurons. Catabolism
of GM2 ganglioside in mammalian cells is undertaken by
β-hexosaminidase, a lysosomal acidic hydrolase. Struc-
turally, β-hexosaminidase (HEX) is comprised of two
subunits, α and β, and exists in three isoforms HEXA
(α/β heterodimer), HEXB (β/β homodimer) and HEXS
(α/α homodimer). In humans, HEXA (α/β) catabolizes
GM2 presented by a third protein named GM2 activator.
Each subunit, α and β, is encoded by a distinct gene,
HEXA and HEXB, located on human chromosomes 15
and 5, respectively. Human patients with HEXA (Tay-Sachs)
or HEXB (Sandhoff) mutations develop storage of GM2
ganglioside in the lysosomes due to the lack of HEXA
(α/β) enzyme activity [1]. Although HEXA enzyme is pre-
sent in all cell types and tissues, neurons are characterized
by remarkably higher concentrations of gangliosides than
other cell types and therefore are highly susceptible to
GM2 lysosomal storage. Similarly to humans, two murine
genes encoding for β-hexosaminidase have been identified:
HexA and HexB [1]. Targeted deletion of the HexA locus
resulted in the development of a mouse phenotype that
showed only a mild degree of the expected pathology and
lack of any neurological findings [1]. In contrast, disrup-
tion of the murine HexB locus resulted in a mouse pheno-
type that closely resembled that of the human disease.
The mice displayed storage of GM2 ganglioside in the cen-
tral nervous system (CNS), and neurons with membran-
ous cytoplasmic bodies similar to those in Tay-Sachs and
Sandhoff patients [1,2]. The phenotypic variation between
humans and mice appears to result from differences in
the ganglioside degradation pathway between the species.
It has been proposed that a second ganglioside degrad-
ation pathway exists in the mouse, whereby GM2 can be,
at least in the absence of HEXA (α/β), metabolized by a
murine sialidase to asialo-GM2 and subsequently catabo-
lized by HEXB (β/β). However, human sialidases cannot
metabolize GM2 ganglioside. Therefore, in the mouse
HexB disruption results in GM2 gangliosidosis, whereas in
* Correspondence: kyrkanides@gmail.com
1Department of Children’s Dentistry, Stony Brook University, Stony Brook, NY
11894-8701, USA
2Health Science Center, Stony Brook University, Stony Brook, NY 11794-8701,
USA
Full list of author information is available at the end of the article
JOURNAL OF 
NEUROINFLAMMATION
© 2012 Kyrkanides et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Kyrkanides et al. Journal of Neuroinflammation 2012, 9:186
http://www.jneuroinflammation.com/content/9/1/186
the human either HEXA or HEXB mutations can cause
GM2 storage. For these reasons, the HexB
−/− knockout
mouse is widely accepted as the appropriate animal model
in the study of GM2 gangliosidosis [1,2].
Clinically, HexB−/− knockout mice display, similarly
to human patients, a near-normal phenotype at birth,
but quickly develop muscle weakness, rigidity, and
motor deterioration typically leading to death at
approximately 4 months of age [1,2]. Progressive neur-
onal GM2 storage is a cardinal characteristic of the
HexB−/− mice, followed by neurodegeneration asso-
ciated with neuronal apoptosis occurring in the central
nervous system [3]. Additional studies have demon-
strated the presence of reactive microglia and astrocytes
in the HexB−/− brain, along with increased levels of
inflammation-related genes [4-7]. Deletion of macrophage-
inflammatory protein (MIP)1α retarded neurodegenera-
tion in the HexB−/− mouse model [8]. Moreover, trans-
plantation of healthy bone marrow to HexB−/− pups
attenuated microglia activation, reduced the extent of
neuronal apoptosis and ameliorated the clinical phe-
notype [5,9]. As the presence of activated microglia
preceded neuronal cell death and reactive microglia
were observed proximal to neurons undergoing apop-
tosis, it was hypothesized that neuroinflammation contri-
butes to neurodegeneration [4,8]. Neuroinflammation
and reactive microglia have also been associated with
neurodegeneration in several other neural diseases
[10,11]. Taken together, the aforementioned studies sug-
gest that microglia activation and neuroinflammation are
contributory to neurodegeneration.
Recent studies in our laboratory focused on the role of
infiltrating peripheral blood mononuclear cells (PBMC)
in the HexB−/− brain. We demonstrated that inhibition
of PBMC infiltration in the brain after deletion of the C-
C chemokine receptor type 2 (CCR2) protein resulted
in partial reduction of neuroinflammation and modest
attenuation of the disease phenotype [12]. However, the
HexB−/−;CCR2−/− mice succumbed due to GM2 storage
and neurodegeneration [12]. Therefore, this data implies
that GM2 neuronal storage is sufficient to elicit neurode-
generation. The goal of this investigation was to evalu-
ate whether GM2 ganglioside storage is necessary for
neurodegeneration and neuroinflammation by pursuing
β-hexosaminidase rescue experiments selectively in the
neurons of HexB−/− mice.
Materials and methods
Cloning
The Thy1-HEXB transgene was engineered by digesting
the pTSC21k (9,098 bp) and pHEXB-IRES-HEXA [5]
vectors with XhoI. Subsequently, HEXB was cloned into
the pTSC21k vector containing the Thy1 promoter,
which was donated by Dr Van der Putten [13]. The final
clone was digested with EcoRV and BamHI to check for
orientation. The final construct was digested with NotI,
and the 11.1 Kb fragment was send to the transgenic
facility to generate transgenic Thy1-HexB mice.
Animals and behavioral analyses
The use of mice and all manipulations and methods per-
tinent to this study were reviewed and approved by the
University of Rochester Animal Resources committee
(IACUC) as well as the Institutional Biosafety Commit-
tee and assigned protocol number 2003–142. HexB+/−
breeders were donated to us by Dr RL Proia (NIH/
NIDDK; Bethesda MD, USA) on a 129 S background,
and genotyped as previously described [7]. Thy1-HEXB
transgenic mice were generated on 129 S background in
the University of Rochester transgenic facility by micro-
injection of the approximately 11.1 Kb linearized DNA
fragment into fertilized oocytes following standard pro-
cedures. Two founder mouse lines (F0) were developed,
of which line no. 2 was able to transmit a functional
copy of the Thy1-HEXB transgene to its offspring. F3
generation transgenic mice were then crossed into the
HexB+/− mouse and their offspring backcrossed into
HexB+/− mice to develop littermates of the desired geno-
type. Genotyping for the Thy1-HEXB transgene was
facilitated by the following primer sets: 5′-AGTCCTGC-
CAGAATTTGATACC-3′ and 5′-ATTCCAAGTTCGA-
CCATCC-3′ at Ta = 58°C. Genotyping for the HexB
locus was performed as previously described [7].
Starting at 9 weeks of age, the mice were trained for
2 weeks on the rotarod appliance (Columbus Instru-
ments, Columbus, OH, USA). At the age of 11 weeks,
we began evaluating the behavioral performance of the
mice by rotarod. Differences between the various animal
groups were assessed by analysis of variance and post
hoc analysis using the Tukey method.
RNA isolation and cDNA synthesis
Tissue was dissected out, frozen in isopentane chilled
with dry ice, and stored in sterile tubes at −80°C until
ready for RNA isolation. RNA was isolated using Trizol
reagent (Invitrogen, Carlsbad, CA, USA), precipitated,
and the concentration determined by spectrophotometry.
A total of 2 μg of RNA was DNase-treated (Invitrogen)
according to the manufacturer’s instructions. First-strand
DNA was synthesized by using 2 μg of DNase-treated
RNA, random hexamers, and Superscript II (Invitrogen)
according to the manufacturer’s instructions.
Quantification of mRNA abundance by real-time reverse
transcription polymerase chain reaction (RT-PCR)
Quantification of mRNA levels was accomplished using
an iCycler (Bio-Rad, Hercules, CA, USA) and real time
quantitative (q)RT-PCR with Taqman probes constructed
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with FAM as the fluorescent marker and Blackhole I
quencher (Biosearch Technologies, Novato, CA, USA).
Prior to PCR of the cDNA samples, PCR conditions
were optimized for each mRNA to be analyzed. Standard
curve reactions were performed by varying annealing
temperatures, primer concentrations, and Taqman probe
concentration. Serial dilution of the starting cDNA tem-
plate demonstrated linear amplification over at least five
orders of magnitude.
PCR reactions were performed in a volume of 25 μl
and contained iQ Supermix (Bio-Rad; 0.625 U Taq,
0.8 mM dNTP, 3 mM Mg2+, 0.2 to 0.6 μM concentra-
tions of each primer, 10 to 100 nM probe and 1 μl of
cDNA sample). To ensure consistency, a master mix was
first prepared containing all reagents except the cDNA
sample. Primers were designed using the Primer Express
(Applied Biosystems) and Oligo 6.83 programs (Molecular
Biology Insights, Inc., Cascade, CO, USA). In general,
PCR reaction conditions were the following: denaturation
at 95°C for 3 minutes, followed by 40 cycles of amplifica-
tion by denaturing at 95°C for 30 s, annealing at 60°C for
30 s and extension at 72°C for 60 s. For each real time
PCR, a standard curve was performed to insure direct lin-
ear correlation between product yield (expressed as the
number of cycles to reach threshold) and the amount of
starting template. The correlation was always greater than
r = 0.925. PCR reaction efficiency (e) was determined for
each reaction. To correct for variations in starting RNA
values, the level of ribosomal 18 S RNA or glyceraldehyde
3-phosphate dehydrogenase (GAPDH) RNA was deter-
mined for all samples and used to normalize all subse-
quent RNA determinations. Normalized threshold cycle
(Ct) values were then transformed using the function
expression = (1+ e) Ct, in order to determine the relative
differences in transcript expression. Data were compared
by analysis of variance (ANOVA) and Tukey’s post hoc
Figure 1 Neuronal β-hexosaminidase (HEX) restitution in Sandhoff mice. (A) The expression of human HEX β/β homodimer (HEXB)
open reading frame was targeted to neurons by the Thy1 promoter. (B) Two transgenic mouse lines were generated. (C) β-Hexosaminidase
expression was detected by immunohistochemistry employing an antibody raised specifically against human HEXB in histology sections
harvested from Thy1-HEXB;HexB−/− brains. (D) As expected, HexB−/− littermates did not express any human HEXB protein. (E) The expression
of HEXB (red) was confirmed by (F) double immunofluorescence (yellow overlap) in (G) neurons (green) in the brains of Thy1-HEXB;HexB−/−
mice. (H) The lack of HEXB expression was confirmed (I) by double immunofluorescence in (J) MHC-II+ microglia/macrophages. Similarly,
there (K) was lack of HEXB expression in astrocytes as detected (L) by the lack of double immunofluorescence in (M) glial fibrillary acidic protein
(GFAP)+ astrocytes.
Kyrkanides et al. Journal of Neuroinflammation 2012, 9:186 Page 3 of 8
http://www.jneuroinflammation.com/content/9/1/186
tests, and by linear regression to determine correlations
using the JMP statistics program (SAS Institute). A prob-
ability of P <0.05 was considered statistically significant.
Cyclo-oxygenase 2 (COX-2) (Ta = 60°): UP-5′-tgacccc-
caaggctcaaata-3′, LP-5′-cccaggtcctcgcttatgatc-3′, PR-5′-
ctttgcccagcacttcacccatcagtt-3′; GAPDH (Ta=60°): UP-5-′
cccaatgtgtccgtcgtg-3′, LP-5′-cctgcttcaccaccttcttg-3′, PR-5′-









The antibody used to detect CD45+ in our experiment
was a rat anti-CD45+ monoclonal antibody commercially
available from Serotec (Raleigh, NC, USA; cat. no.
MCA43G) at 1:400 dilution, coupled with a rabbit anti-
rat IgG secondary antibody (Jackson Immunoresearch;
West Grove, PA, USA). Activated astrocytes were identi-
fied by a mouse anti-glial fibrillary acidic protein (GFAP)
monoclonal antibody (1:400 dilution; Chemicon INTL,
Temecula, CA, USA; clone GA-5). Activated denditric
cells/microglia/macrophages were stained with a rat
anti-major histocompatibility complex class II (MHC-II;
Bachem, Torrance, CA, USA; clone ER-TR3). GM2
ganglioside was immunolocalized employing a mouse
anti-N-acetyl GM2 monoclonal IgM antibody (Seika-
gaku, East Falmouth, MA, USA; clone MK1-16). These
antibodies were coupled with appropriate secondary
antibodies: rabbit anti-goat IgG biotin-conjugated, goat
anti-mouse IgG Fab biotin conjugated, goat anti-rat IgG
biotin-conjugated antibodies and goat anti-mouse IgM
biotin conjugated, respectively (Jackson Immunore-
search). Human HEXB was detected by a goat anti-
HEXB polyclonal antibody (Proia RL, NIH/NIDDK,
Bethesda MD, U.S.A.) coupled with a rabbit anti-goat
IgG secondary antibody (Jackson Immunoresearch).
Visualization was performed utilizing 3,3-diaminobenzi-
dine (DAB)-nickel as chromagen. The glass slides were
then dehydrated through multiple ethanol solutions,
cleared through xylene and coverslipped using DPX per-
manent mounting medium (Fluka, Neu-Ulm, Switzer-
land). The tissue sections were then studied under a
BX51 Olympus light microscope and color microphoto-
graphic images were captured as described above. The
total numbers of GFAP+ and MHC-II+ cells were
counted in ten random microscopic fields (40 ×): in each
field, the number of positive cells was counted, and
averages and standard errors of mean were calculated
for each area of the brain.
Figure 2 GM2 ganglioside storage in the Thy1-HEXB;HexB
−/− brain. (A) Wild-type mice did not display any GM2 storage as detected by
immunohistochemistry (black staining) employing a monoclonal antibody. (B) The expression of human HEXB in the neurons of HexB−/− mice
driven by the Thy1 promoter resulted amelioration of GM2 storage, as seen by the lack of any significant GM2 immunoreactivity in 4-month-old
Thy1-HEXB;HexB−/− mouse brain compared to (C) HexB−/− littermates. (D) Glial fibrillary acidic protein (GFAP)+ astrocytes (E) did not contain, as
detected by the lack of double immunofluorescence, the presence of (F) GM2 ganglioside. However, (G) major histocompatibility complex class II
(MHC-II)+ microglia/macrophages contained, as detected (H) by double immunofluorescence, the presence of (I) GM2 ganglioside. Bar = 100 μM.
HEXB= β-hexosaminidase β/β homodimer.
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Results
Conditional restoration of β-hexosaminidase in neurons
rescued HexB−/− mice from GM2 ganglioside storage
Conditional restitution of β-hexosaminidase in the neu-
rons of HexB−/− mice was accomplished by driving the
expression of the human HEXB cDNA by the neuron
specific Thy1 promoter in transgenic mice (Figure 1A).
Two founder lines were generated in the 129 S strain
background, of which line no. 2 successfully transmitted
the transgene to the offspring (Figure 1B). Trans-
genic mice derived from founder mouse line no. 2
were subsequently crossed into the HexB−/− knockout
mouse colony (129 S background strain) for the dev-
elopment of Thy1-HEXB;HexB−/− compound mice. The
Thy1-HEXB;HexB−/− were characterized by expres-
sion of human HEXB in neurons (Figure 1C). As
expected, HexB−/− mice did not display any human
HEXB expression (Figure 1D). Double immunofluorescence
analysis confirmed the expression of human HEXB in
neuron (Figure 1E-G), but not MHC-II+ microglia/
macrophages (Figure 1H-J) or GFAP+ astrocytes
(Figure 1K-M).
Immunohistochemical analysis revealed the lack of GM2
ganglioside in wild-type mice (Figure 2A) and comparable
low levels in the Thy1-HEXB;HexB−/− compound mice
(Figure 2B), compared to HexB−/− knockout mice, which
are known to develop GM2 storage in neurons (Figure 2C).
Further analysis by double immunofluorescence analysis
revealed that GFAP+ astrocytes do not contain any GM2
ganglioside in the Thy1-HEXB;HexB−/− mouse model
(Figure 2D-F). Conversely, MHC-II+ microglia/macro-
phages displayed the presence of GM2 ganglioside content
in the Thy1-HEXB;HexB−/− mouse model despite the
restoration of HEXB activity in neurons (Figure 2G-I).
β-Hexosaminidase restitution in the brain of HexB−/− mice
did not abolish brain inflammation
Brain inflammation was assessed by evaluating transcript
(mRNA) levels for key inflammatory genes in total RNA
brain extracts, as well as by assessing the presence of
reactive astrocytes and microglia in histology brain
sections. Astrocyte activation was evaluated by GFAP
immunohistochemistry. Microglia activation was assessed
by MHC-II+ and CD45+ immunohistochemistry. As
Figure 3 Neuronal β-hexosaminidase (HEX) restitution does not reduce brain inflammation in adult HexB−/− mice. (A) Adult wild-type
brains lacked any major histocompatibility complex class II (MHC-II) immunoreactive cells, whereas (B) HexB−/− brains were characterized by
the presence of MHC-II positive cells, a marker of myeloid-derived immune cells, throughout the brain parenchyma. (C) The 4-month-old
Thy1-HEXB;HexB−/− littermates were also characterized by the presence of MHC-II positive cells in their brain. Another marker of myeloid-derived
immune cells expressed in high levels by peripheral blood macrophages/monocytes intensely is CD45+. (D) Wild-type mice were characterized
by the lack of CD45+-positive cells, whereas (E) HexB−/− mice display high numbers of CD45+ cells, also (F) present in the brains of Thy1-HEXB;
HexB−/− littermates. Moreover, we evaluated the presence of reactive astrocytes in the mouse brains by glial fibrillary acidic protein (GFAP)
immunohistochemistry. (G) Wild-type mice lacked GFAP+ cells (activated astrocytes) in their cortex. Conversely, (H) HexB−/− mice (4 months old)
displayed GFAP+ astrocytes throughout their brain parenchyma, as well as (I) in the brain of Thy1-HEXB;HexB−/− littermates. Bar = 100 μM.
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anticipated, HexB−/− mice were characterized by the
presence of GFAP, MHC-II+ and CD45+ cells throughout
their brain parenchyma (Figures 3B and 4A), as well as
significant upregulation in key inflammatory genes in
their brain (Figure 4B). Conversely, we observed a reduc-
tion in the number of MHC-II+ and CD45+ cells in
the brain parenchyma of Thy1-HEXB; HexB−/− mice at a
significant degree (Figure 4A). CD45+ immunoreactivity
was employed as a marker of infiltrating macrophages/
monocytes, as CD45+ is expressed at high levels by acti-
vated myeloid derived immune cells [7,12]. CD45+ is also
expressed by other immune cells, however at low levels
(detectable by flow cytometry) that fall below the detec-
tion threshold of our immunohistochemical method.
Moreover, there was a significant downregulation of
TNFα and MHC-II transcript in Thy1-HEXB;HexB−/−
brains (Figure 4B). Interestingly, there were no changes in
the number of activated astrocytes in the HexB−/− versus
Thy1-HEXB;HexB−/− mouse brains (Figures 3H-I and
4A). To this end, there was a significant downregulation
in some inflammatory genes (Figure 4B), including TNFα
and MHC-II, but not in others (GFAP, IL-1β, COX-2).
Restoration of neuronal function rescues HexB−/− mice
from neurodegeneration
Neuronal β-hexosaminidase restitution in the Thy1-
HEXB;HexB−/− mice led to amelioration of neurodegen-
eration and normalization of the clinical phenotype,
despite the partial reduction in neuroinflammation. Neu-
rodegeneration was evaluated clinically by rotarod test
as well as by caspase-3 immunohistochemistry in brain
histology sections. As expected, HexB−/− mice were
characterized by a significant decline in motor behavior
starting at 14 weeks of age, followed by complete clinical
deterioration by 17 weeks of age (Figure 4C) when they
were killed according to approved animal use protocols.
Conversely, Thy1-HEXB;HexB−/− mice performed on
the rotarod test similar to wild-type mice for the total
duration of the experiment (Figure 4C). Further, we
have followed these mice for over 12 months and they
continuously display normal motor behavior. Further-
more, caspase-3 immunoreactivity was reduced to wild-
type levels in the Thy1-HEXB;HexB−/− mice, whereas
HexB−/− mice displayed extensive caspase-3 immunos-
taining (Figure 5).
Figure 4 Rescue of HexB−/− mice from GM2 storage has limited effect on neuroinflammation. Targeted rescue of β-hexosaminidase
deficiency selectively in the neurons of HexB−/− mice (A) significantly reduced the number of major histocompatibility complex class II (MHC-II)+
and CD45+ cells in the brain, but not of glial fibrillary acidic protein (GFAP)+ astrocytes. (B) We also observed downregulation in the expression
of the tumor necrosis factor α (TNFα) and MHC-II genes, but not of interleukin (IL)-1β, GFAP or cyclo-oxygenase 2 (COX-2) in 4-month-old
Thy1-HexB;HexB−/− mice compared to HexB−/− littermates. (C) Interestingly, the Thy1-HexB;HexB−/− mice were characterized by fully rescued
neurological phenotype, assessed by rotarod, even in the presence of reactive astrocytes and retained brain inflammation. Caspase-3 levels were
evaluated in the brain as a measure of neurodegeneration. ***P <0.001; **P <0.01; *P <0.05.
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Discussion
In order to elucidate the role of GM2 ganglioside storage
in neurodegeneration and neuroinflammation, we
restored β-hexosaminidase selectively in the neurons
HexB−/− mice targeting the expression of the human
HEXB by the Thy1 neuron specific promoter selectively
in neurons. Our results demonstrated that Thy1-HEXB;
HexB−/− mice were rescued from GM2 neuronal stor-
age and displayed normal clinical phenotype. This set
of data proves that β-hexosaminidase restoration in
neurons is sufficient for the rescue of mice from GM2
gangliosidosis. Although this finding was anticipated, as
β-hexosaminidase deficiency is pathognomonic in GM2
gangliosidosis [1], we observed a significant number of
prevailing MHC-II+ cells, a marker of activated microglia
and myeloid derived immune cells, including peripheral
blood macrophages and monocytes, in the brain of the
Thy1-HEXB;HexB−/− mice. Upon further analysis, we
identified the presence of GM2 ganglioside specifically in
MHC-II+ cells (Figure 2); conversely, we did not find
GM2 in astrocytes. Moreover, we confirmed the identity
of cells expressing human HEXB in the Thy1-HEXB;
HexB−/− mice to be selectively neurons. Taken together,
these data suggest that GM2 is likely phagocytosed by
microglia/macrophages, underlying the increased num-
ber of MHC-II+ cells in the brain of the Thy1-HEXB;
HexB−/− mice (Figure 4). The presence of GM2 in micro-
glia/macrophages is surprising, as it was anticipated that
human HEXB would be secreted by neurons in the
extracellular milieu and from there taken up by neigh-
boring cells, a key characteristic of lysosomal enzymes
[14]. The presence of GM2 along with lack of human
HEXB in microglia/macrophages suggests that HEXB
crosscorrection between different cell types in the Thy1-
HEXB;HexB−/− model is not efficient. The number of
GFAP+ astrocytes was also increased in the HexB−/− and
Thy1-HEXB;HexB−/− mice compared to littermate con-
trols. Moreover, we did not observe the colocalization of
GFAP with HEXB or GM2, implying that astrocyte acti-
vation is presumably secondary to microglia/macrophage
activation. Taken together, our data suggest that in the
Thy1-HEXB;HexB−/− mouse model, HEXB is expressed
selectively in neurons under the Thy1 promoter, leading
to GM2 clearance in neurons. Microglia and infiltrating
macrophages also participate in GM2 clearance, but
unlike neurons, they are unable to catabolize GM2,
which accumulates over time in their cytoplasm and
activates them. Astrocytes do not express HEXB nor
phagocytose GM2, but appear to become activated pre-
sumably from cell-cell interactions (for example micro-
glia-astrocyte). Previous studies in our laboratory have
also associated TNFα upregulation with microglia
activation and monocyte/macrophage infiltration in
the HexB−/− brain [12]. To this end, we have pre-
viously demonstrated how activated microglia are cap-
able of activating in turn astrocytes via IL-1β and TNFα
[15], cytokines which were found elevated in the Thy1-
HEXB;HexB−/− mouse brains. Despite the presence of
Figure 5 Caspase-3 expression is reduced in Thy1-HexB;HexB−/− mice. Caspase-3 immunoreactivity was employed as a measure of
neurodegeneration. (A) Thy1-HexB;HexB−/− mice lacked any detectable caspase-3 expression, as assessed by immunohistochemistry.
(B) Conversely, HexB−/− mice displayed intense caspase-3 immunoreactivity located in cortical neurons. (C) Wild-type mice did not present
any caspase-3 immunostaining in their brain. (D) Cell counts of caspase-3 immunopositive cells was reduced significantly in Thy1-HexB;HexB−/−
mice, to levels observed in wild-type mice. Bar = 100 μM. ***P <0.001; **P <0.01; *P <0.05.
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neuroinflammation, Thy1-HEXB;HexB−/− mice exhibit
no signs of neurodegeneration, both clinical and neu-
ropathological (expression of the proapoptotic gene
caspase-3 was ameliorated). Our results suggest that the
attendant neuroinflammation is not sufficient to elicit
neurodegeneration or to affect normal mouse behavior.
This finding agrees with previous report by other investi-
gators that have shown neuroinflammation to play a
contributory, but not pathognomonic, role in GM2 gang-
liosidosis [4,5,8] and other neurodegenerative diseases
[10,11,16].
In conclusion, the present study demonstrated that
restoration of neuronal function is paramount for the
treatment of neurodegeneration in the Sandhoff disease
mouse model, notwithstanding the contributory role of
neuroinflammation to neurodegeneration. Moreover, our
study demonstrated that the level of attendant neuroin-
flammation in the Thy1-HEXB;HexB−/− model is insuffi-
cient to elicit neurodegenerative or behavioral changes
in mice.
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